HIGHLIGHTS
SUMMARY
Of any retained studies of the first screening step. Although alteplase remains the only approved thrombolytic for treatment of AIS in the United_States, tenecteplase offers theoretical and practical advantages when compared to alteplase. Despite multiple RCTs and prospective studies comparing tenecteplase to alteplase for AIS, tenecteplase is not yet approved for the treatment of AIS in the United_States, although other countries have approved its use. Since then, eight more RCTs have been published comparing tenecteplase to alteplase, with three trials being published in 2022 alone. The NOR-TEST-2, part A reported by Kvistad . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.